171. Wilson disease Clinical trials / Disease details
Clinical trials : 68 / Drugs : 79 - (DrugBank : 17) / Drug target genes : 3 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04526197 (ClinicalTrials.gov) | July 8, 2020 | 19/8/2020 | Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. | A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. | Wilson Disease | Drug: ALXN1840;Drug: Celecoxib | Alexion Pharmaceuticals | NULL | Completed | 18 Years | 50 Years | All | 36 | Phase 1 | United States |